Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies
about
Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target DrugsKey Targets for Multi-Target Ligands Designed to Combat NeurodegenerationAntinociceptive Activity of Borreria verticillata: In vivo and In silico Studies.Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases.Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs.In silico repurposing of antipsychotic drugs for Alzheimer's disease.The Forty-Sixth Euro Congress on Drug Synthesis and Analysis: Snapshot †.Computer-aided design of multi-target ligands at A1R, A2AR and PDE10A, key proteins in neurodegenerative diseases.Combining in vitro and in silico approaches to find new drugs targeting the pathological proteins related to the Alzheimer's disease.Blood brain barrier and Alzheimer's disease: Similarity and dissimilarity of molecular alerts.Tailored Approaches in Drug Development and Diagnostics: From Molecular Design to Biological Model Systems.A perspective on multi-target drug discovery and design for complex diseases.Revolution of Alzheimer Precision Neurology Passageway of Systems Biology and Neurophysiology.MetStabOn-Online Platform for Metabolic Stability Predictions.Polypharmacology of conformationally locked methanocarba nucleosides.Hydroxybenzoic Acid Derivatives as Dual-Target Ligands: Mitochondriotropic Antioxidants and Cholinesterase Inhibitors.Computer-Aided Multi-Target Management of Emergent Alzheimer's Disease.Bis(9)-(-)-Meptazinol, a novel dual-binding AChE inhibitor, rescues cognitive deficits and pathological changes in APP/PS1 transgenic mice
P2860
Q28074736-390B3E17-5F50-4DCE-8EAD-48144765F4A2Q28077589-859F3E3F-8E1C-4ECB-BB1A-C1D39ED5317BQ33710983-6C47B46D-3D7C-48DD-86D1-68A6D84D66CBQ38998475-F295CA66-4541-4130-A7C0-30F8163B7164Q39438767-283A1D66-D431-4CAE-9B80-B892EF79C9C7Q42610044-7449F6EA-BCA9-425F-9F9A-0C1C5B4CEDF9Q47215879-E5B63555-75F0-4B61-808A-FD4C51C48678Q47242194-42F87C24-DF57-4895-B259-D0C0D9C01F4DQ47396500-426D463C-6A3B-443C-A4DF-9A6453F1661AQ47643043-3A00EC53-4996-46D7-BB6F-22FB797A577CQ47690085-20E3560A-2451-41F2-8792-730F3C7AEB4CQ49226937-4020BB67-E6FA-46E4-AC16-77363245809CQ51760905-9336F46C-5958-45E1-A417-DFB17E31EBEBQ52337060-2BD3402C-3BFC-4462-AD23-A5AB5A35568EQ53123581-5BDBC621-AA97-4D31-B454-C0D5C52FA43DQ55007733-429687E2-A020-44AE-9493-710E5A37EF2BQ55456183-0445D885-98CD-42DF-9692-98EEB4E59978Q58750273-4F38A1C8-4D2F-4E08-BCD7-159BBB843D80
P2860
Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Drug Design for CNS Diseases: ...... irtual Screening Methodologies
@ast
Drug Design for CNS Diseases: ...... irtual Screening Methodologies
@en
Drug Design for CNS Diseases: ...... irtual Screening Methodologies
@nl
type
label
Drug Design for CNS Diseases: ...... irtual Screening Methodologies
@ast
Drug Design for CNS Diseases: ...... irtual Screening Methodologies
@en
Drug Design for CNS Diseases: ...... irtual Screening Methodologies
@nl
prefLabel
Drug Design for CNS Diseases: ...... irtual Screening Methodologies
@ast
Drug Design for CNS Diseases: ...... irtual Screening Methodologies
@en
Drug Design for CNS Diseases: ...... irtual Screening Methodologies
@nl
P2093
P2860
P50
P3181
P356
P1476
Drug Design for CNS Diseases: ...... irtual Screening Methodologies
@en
P2093
Danica Agbaba
Jelica Vucicevic
Lazaros Mavridis
Teodora Djikic
P2860
P3181
P356
10.3389/FNINS.2016.00265
P407
P577
2016-06-10T00:00:00Z